Sign in
WithdrawnNo phase

Assessing Superion Clinical Endpoints vs. Decompression

Key facts

Who runs it
VertiFlex, Incorporated
Where
Birmingham, Carlsbad, Celebration, Shreveport, and Willow Grove, United StatesSee the 5 sites
Trial code
Status
Withdrawn
Started
8 Feb 2017
Ended
31 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Superion® IDS
  • Direct decompression Surgery
Record updated
12 June 2019
Why it stopped
FDA and Sponsor closed trial. New post-marketing approval trial in development.

Who can take part

Age
45 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • Male or female subjects ≥ 45 years of age
  • Persistent leg/buttock/groin pain, with or without back pain that is consistently relieved by flexion activities (example: sitting or bending over a shopping cart)
  • Subjects who have been symptomatic and undergoing conservative care treatment for at least 6 months, without relief
  • Diagnosis of degenerative spinal stenosis of the lumbar spine, defined as the narrowing of the midline sagittal spinal canal (central) and/or narrowing between the facet superior articulating process (SAP), the posterior vertebral margin (lateral access), and the nerve root canal (foraminal)
  • Radiographic confirmation of at least moderate spinal stenosis which narrows the central, lateral, or foraminal spinal canal at one or two contiguous levels from L1-L5. Moderate spinal stenosis is defined as ≤50% reduction in lateral/central foramen
  • Must present with moderately impaired Physical Function (PF) defined as a score of ≥ 2.0 of the Zurich Claudication Questionnaire (ZCQ)
  • Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained
  • Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, cooperate with the investigational procedures and are willing to return for all the required post-treatment follow-ups; Note: In Criteria #5, all imaging used to confirm LSS should be completed within 4 weeks prior to enrollment. Radiographic confirmation of LSS may include MRI and/or CT

Who cannot take part

  • Diagnosis of lumbar spinal stenosis which, if the patient were randomized to the Superion arm, would not require any direct neural decompression or surgical intervention other than that required to implant the Superion® device or if randomized to the direct decompression arm, would not require a decompression procedure which would create significant instability requiring spinal fusion, with or without instrumentation
  • Lumbar spinal stenosis at more than two levels determined pre-operatively to require surgical intervention
  • Prior surgery of the lumbar spine at the treatment level(s)
  • Currently undergoing immunosuppressive therapy or long-term steroid use
  • Enrolled in the treatment phase of another drug or device clinical investigation (currently within past 30 days)
  • Significant peripheral vascular disease (diminished dorsalis pedis or tibial pulses)
  • Cauda equina syndrome (defined as neural compression causing neurogenic bowel or bladder dysfunction)
  • Active (systemic, or local in disc or spine) infection at time of surgery
  • Active systemic disease such as AIDS, HIV, hepatitis, etc
  • Paget's disease at involved segment or metastasis to the vertebrae, osteomalacia, or other metabolic bone disease
  • Known allergy to titanium or titanium alloys
  • Tumor in the spine or a malignant tumor except for basal cell carcinoma
  • Known or suspected history of alcohol and/or drug abuse
  • Any condition that, in the opinion of the Investigator, would affect the patient's welfare or outcome of the clinical trial
  • Axial back pain only
  • Fixed motor deficit in lower extremity(ies)
  • Unremitting pain in any spinal position
  • Significant peripheral neuropathy or acute denervation secondary to radiculopathy
  • Significant instability of the lumbar spine as defined by ≥ 3mm translation or ≥ 5° angulation through flexion/extension films
  • Sustained pathologic fractures of the vertebrae or multiple fractures of the vertebrae and/or hips
  • Spondylolisthesis or degenerative spondylolisthesis greater than grade 1 (on a scale of 1-4)
  • Spondylosis (pars fracture) at the treatment level(s)
  • Degenerative lumbar scoliosis with a Cobb angle of > 10° at treatment level
  • Osteoporosis, defined as a DEXA bone density measurement T score ≤ -2.5
  • Morbid obesity, defined as Body Mass Index (BMI) >40kg/m2
  • Prisoner or transient
  • Life expectancy less than two years
  • Any significant psychological disturbance, psychotic or neurotic, that could impair the consent process or ability to complete subject self-report questionnaires
  • Involved in pending litigation of the spine or worker's compensation related to the back
  • Congenital defect of the spine
  • Pregnant or lactating

Where in United States

  • Alabama Clinical Therapeutics, LLCBirmingham, United States
  • Coastal Pain Spinal DiagnosticsCarlsbad, United States
  • Lake Nona Medical ArtsCelebration, United States
  • Spine Institute of LouisianaShreveport, United States
  • Rothman InstituteWillow Grove, United States

About the trial

What the trial wants to find out

PURPOSE: The primary purpose of this study is to demonstrate that the Composite Clinical Success of the study group receiving the Superion® IDS is not inferior to the success rate observed in the study group treated by direct decompression at 60 months follow-up. Secondarily, the trial is intended to establish that Composite Clinical Success of the study group receiving the Superion® IDS at 24 months is not inferior to the success rate observed at 24 months in patients treated with the Superion® IDS in the original IDE trial. Thirdly, the trial is intended to establish that Composite Clinical Success of the population receiving the Superion® IDS in this trial at 24 months is not inferior to the success rate observed at 24 months in patients treated with direct decompression.

The 2 groups in the trial

  • Indirect Decompression SystemExisting treatment, for comparison

    Superion® IDS surgical procedure

    Treatment: Superion® IDS

  • Direct decompression SurgeryExisting treatment, for comparison

    Open, direct decompression surgical procedure

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A 2 and 5 Year Comparative Evaluation of Clinical Outcomes in the Treatment of Moderate Lumbar Spinal Stenosis With the Superion® Indirect Decompression System (IDS) vs. Direct Decompression Surgery for FDA Actual Conditions of Use Study
Record updated
12 June 2019